MA35860B1 - Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a - Google Patents

Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a

Info

Publication number
MA35860B1
MA35860B1 MA37201A MA37201A MA35860B1 MA 35860 B1 MA35860 B1 MA 35860B1 MA 37201 A MA37201 A MA 37201A MA 37201 A MA37201 A MA 37201A MA 35860 B1 MA35860 B1 MA 35860B1
Authority
MA
Morocco
Prior art keywords
enzyme inhibitors
quinoline derivatives
compounds
pde10a enzyme
relates
Prior art date
Application number
MA37201A
Other languages
English (en)
Inventor
Morten Langgård
Jan Kehler
Jacob Nielsen
Ask Püschl
John Paul Kilburn
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48667762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35860(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA35860B1 publication Critical patent/MA35860B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des dérivés de quinoléine de formule (i) qui sont des inhibiteurs d'enzyme pde10a, et en tant que tels sont utiles pour traiter des troubles neurodégénératifs et psychiatriques. En particulier, l'invention concerne des composés qui sont très sélectifs pour pde10 par rapport aux autres sous-type de pde. La présente invention concerne en outre des compositions pharmaceutiques comprenant des composés de l'invention et des procédés de traitement de troubles en utilisant les composés de l'invention.
MA37201A 2011-12-21 2014-07-11 Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a MA35860B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201100990 2011-12-21
PCT/EP2012/076590 WO2013092974A1 (fr) 2011-12-21 2012-12-21 Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a

Publications (1)

Publication Number Publication Date
MA35860B1 true MA35860B1 (fr) 2014-12-01

Family

ID=48667762

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37201A MA35860B1 (fr) 2011-12-21 2014-07-11 Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a

Country Status (32)

Country Link
US (2) US9216986B1 (fr)
EP (1) EP2794606A1 (fr)
JP (1) JP6073918B2 (fr)
KR (1) KR20140105574A (fr)
CN (1) CN104114554A (fr)
AP (1) AP2014007697A0 (fr)
AR (1) AR089361A1 (fr)
AU (1) AU2012356885B2 (fr)
BR (1) BR112014015192A8 (fr)
CA (1) CA2859702A1 (fr)
CL (1) CL2014001643A1 (fr)
CO (1) CO6990727A2 (fr)
CR (1) CR20140289A (fr)
DO (1) DOP2014000141A (fr)
EA (1) EA028824B1 (fr)
EC (1) ECSP14010000A (fr)
GE (1) GEP201706657B (fr)
HK (1) HK1202861A1 (fr)
IL (1) IL233226A (fr)
MA (1) MA35860B1 (fr)
MD (1) MD20140070A2 (fr)
MX (1) MX348792B (fr)
MY (1) MY165216A (fr)
PE (1) PE20141945A1 (fr)
PH (1) PH12014501434A1 (fr)
RU (1) RU2624440C2 (fr)
SG (1) SG11201403339YA (fr)
TN (1) TN2014000268A1 (fr)
TW (1) TWI570124B (fr)
UA (1) UA111871C2 (fr)
WO (1) WO2013092974A1 (fr)
ZA (1) ZA201404533B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
US9670230B2 (en) 2012-11-29 2017-06-06 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
KR20060030483A (ko) 2003-06-30 2006-04-10 알타나 파마 아게 Ｐｄｅ10 억제제로서 피롤로디히드로이소퀴놀린
CA2530114A1 (fr) 2003-06-30 2005-01-13 Altana Pharma Ag Derives de pyrrolo-dihydroisoquinoline comme inhibiteurs de pde10
WO2005012485A2 (fr) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
JP2007523152A (ja) 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
EP1755611A1 (fr) 2004-06-07 2007-02-28 Pfizer Products Inc. Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
US8598355B2 (en) * 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
WO2010145668A1 (fr) 2009-06-19 2010-12-23 H. Lundbeck A/S Nouveau dérivé de phénylimidazole en tant qu'inhibiteur de l'enzyme pde10a
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
CA2800618C (fr) * 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Composes heteroaryles et leurs procedes d'utilisation
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物

Also Published As

Publication number Publication date
WO2013092974A1 (fr) 2013-06-27
NZ626279A (en) 2015-07-31
EA028824B1 (ru) 2018-01-31
AR089361A1 (es) 2014-08-20
US20150376186A1 (en) 2015-12-31
MX2014007409A (es) 2014-08-01
BR112014015192A2 (pt) 2017-06-13
AU2012356885B2 (en) 2016-09-08
AU2012356885A1 (en) 2014-07-10
GEP201706657B (en) 2017-04-25
PH12014501434B1 (en) 2014-09-22
CA2859702A1 (fr) 2013-06-27
TW201339156A (zh) 2013-10-01
KR20140105574A (ko) 2014-09-01
IL233226A (en) 2017-11-30
SG11201403339YA (en) 2014-07-30
RU2624440C2 (ru) 2017-07-04
TN2014000268A1 (en) 2015-09-30
ZA201404533B (en) 2015-12-23
US9801878B2 (en) 2017-10-31
AP2014007697A0 (en) 2014-06-30
PH12014501434A1 (en) 2014-09-22
MD20140070A2 (ro) 2014-12-31
MX348792B (es) 2017-06-29
EP2794606A1 (fr) 2014-10-29
IL233226A0 (en) 2014-08-31
ECSP14010000A (es) 2015-12-31
CO6990727A2 (es) 2014-07-10
US9216986B1 (en) 2015-12-22
DOP2014000141A (es) 2014-07-31
JP2015502970A (ja) 2015-01-29
JP6073918B2 (ja) 2017-02-01
US20160303120A1 (en) 2016-10-20
RU2014127984A (ru) 2016-02-10
CN104114554A (zh) 2014-10-22
UA111871C2 (uk) 2016-06-24
CL2014001643A1 (es) 2014-11-21
HK1202861A1 (en) 2015-10-09
PE20141945A1 (es) 2014-12-18
CR20140289A (es) 2014-08-18
EA201491152A1 (ru) 2015-01-30
MY165216A (en) 2018-03-09
TWI570124B (zh) 2017-02-11
BR112014015192A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA37958A1 (fr) Pde9i ayant un squelette imidazo pyrazinone
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA33768B1 (fr) Triazolopyridines
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA34797B1 (fr) Hétéroaryles et leurs utilisations
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
PH12013502695A1 (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UA111198C2 (uk) Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
PH12014501434A1 (en) Quinoline derivatives as pde10a enzyme inhibitors
MA45367B1 (fr) Inhibiteurs de la tyrosine kinase
MA37836A1 (fr) Antagonistes du récepteur 5-ht3